Cemp, A Mitoxantrone Containing Combination, in the Treatment of Intermediate and High Grade Non-Hodgkin's Lymphoma: An Effective and Non Toxic Therapeutic Alternative for Adult and Elderly Patients: On behalf of Non-Hodgkin's Lymphoma Co-operative Study Group (NHLCSG)

Leukemia and Lymphoma

Volumn 41, Issue 42006, 2001, Pages 125-136

  Chisesi, T ^a   Polistena, P ^a   Contu, A ^b   Coser, P ^c   Indrizzi, L ^d   Leoni, P ^e   Majolino, I ^f   Porcellini, A ^d   Salvagno, L ^d   Zambaldi, G ^g   Rizzoli, V ^h   Congiu, A M ⁱ   Santini, G ⁱ  

^a Ospedale Civile SS   (Italy)

^b SS Annunziata Hospital   (Italy)

^c Ospedale Civile   (Italy)

^d Ospedale Civile   (Italy)

^e UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^f SAN GIOVANNI ADDOLORATA HOSPITAL   (Italy)

^g Ospedale Civile di Arco   (Italy)

^h UNIVERSITY OF PARMA   (Italy)

ⁱ Ospedale Civile   (Italy)

Author keywords

combination therapy; mitoxantrone; NHL; non Hodgkin's lymphoma

Indexed keywords

CYCLOPHOSPHAMIDE; ETOPOSIDE; LACTATE DEHYDROGENASE; MITOXANTRONE; PREDNISONE;

ADULT; AGED; ALLERGY; ALOPECIA; ARTICLE; BONE MARROW DISEASE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER MORTALITY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPARATIVE STUDY; CONSCIOUSNESS DISORDER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL DISEASE; HEART DISEASE; HEMATOLOGIC DISEASE; HUMAN; INFECTION; KIDNEY DISEASE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONHODGKIN LYMPHOMA; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPLEEN DISEASE; STOMATITIS; SURVIVAL RATE; SYMPTOM; SYSTEMIC DISEASE; TREATMENT OUTCOME;

ACTUARIAL ANALYSIS; AGE FACTORS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; ETOPOSIDE; FEMALE; HUMANS; LYMPHOMA, HIGH-GRADE; LYMPHOMA, INTERMEDIATE-GRADE; MALE; MIDDLE AGED; MITOXANTRONE; PREDNISONE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0035070118     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428190109057961     Document Type: Article

References (28)

1. Rabkin C. S., Devessa S. S., Zahm O. S., Gail M. H. Increasing incidence of non-Hodgkin's lymphoma. Seminars in Hematology 1993; 30: 286 – 96
2. Jones S. E., Fuks Z., Bull M., et al. Non-Hodgkin's lymphomas IV. Clinicopathologic correlation in 405 cases. Cancer 1987; 34: 1173 – 86
3. Carbone A., Tirelli U., Volpe R., et al. Non-Hodgkin's lymphoma in the elderly. A retrospective clinicophatologic study of 50 patiens. Cancer 1986; 57: 2185 – 89
4. D'Amore F., Brincker H., Christensen B. E., et al. Non-Hodgkin's lymphomas in the elderly. Annals of Oncology 1992; 3: 379 – 86
5. Kwak L. W., Halpern J., Olshen R. A., et al. Prognostic significance of actual dose intensity in diffuse large cell lymphoma: results of a tree-structured survival analysis. Journal of Clinical Oncology 1990; 8: 963 – 77
6. The International Non-Hodgkin's Lymphoma Prognostic Factor Project. A predictive model for aggressive Non-Hodgkin's lymphoma. New England Journal of Medicine 1993; 329 – 987
7. Repetto L., Vercelli M., Simoni A., et al. Comorbid condition among elderly cancer patients [abstract]. Annals of Oncology 1994; 5: 58, abstr. 0288
8. Lipschitz D. Age-related declines in hematopoietic reserve capacity. Seminars in Oncology 1995; 22 (Suppl. 1) 3 – 5
9. Shenkenberrg T. D., Von Hoff D. D. Mitoxantrone: a new anticancer drug with significant clinical activity. Annals of Internal Medicine 1986; 105: 67 – 81
10. Durr E. F. Biologic and biochemical effects of Mitoxantrone. Seminars in Oncology 1984; 11 (Suppl. 1) 3
11. Contu A., Olmeo N., Schintu G. M., et al. II Mitoxantrone nei linfomi non-Hodgkin. I linfomi non-Hodgkin dell'adulto 1989; 119 – 22
12. Santini G., Contu A., Porcellini A., et al. Mitoxantrone alone or in combination chemotherapy (VeMP) as second-line treatment in relapse or refractory poor-prognosis Non-Hodgkin's Lymphoma. A report of the Non-Hodgkins Lymphoma Co-operative Study Group (NHLCSG). Haematologica 1991; 76: 485 – 90
13. Chisesi T. The rationale of the therapy with Mitoxantrone in Non-Hodgkin's Lymphoma. Leukemia and Lymphoma 1993; 9: 63 – 9
14. Oken M., Creech R., Tormey D. Toxicity and response criteria of the Eastern Coopertive Oncology Group. American Journal of Clinical Oncology 1982; 5: 596
15. Kaplan E. L., Meier P. Nonparametric estimation from incomplete observations. Journal of the American Statistic Association B 1958; 53: 457 – 81
16. Cox D. R. Regression models and life tables. JR Stat Soc B 1972; 34: 187 – 220
17. Dixon D. O., Neilan B., Jones S. E., et al. Effect of age on outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience. Journal of Clinical Oncology 1988; 4: 295 – 305
18. Armitage J. O., Potter J. F. Aggressive chemotherapy for diffuse histiocitic lymphoma in the elderly: increased complication of advancing age. Journal of the American Geriatric Society 1984; 32: 269 – 73
19. Dixon D. O., Neilan B., Jones S. E., et al. Effect of age on therapeutic outcome in adavanced diffuse histiocitic lymphoma: the Soutwest Oncology Group experience. Journal of Clinical Oncology 1986; 4: 295 – 305
20. Miller T. P., Jones S. E. Initial chemotherapy for clinically localized lymphomas of unfavorable histology. Blood 1983; 62: 413 – 18
21. Martelli M., Guglielmi C., Coluzzi, et al. P-VABEC: a prospective study of a new weekly chemotherapy regimen for elderly aggressive non-Hodgkin's lymphoma. Journal of Clinical Oncology 1993; 12: 2362 – 69, vol 11
22. Gomez H., Mas L., Casanova L., et al. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity. Journal of Clinical Oncology 1998; 7: 2352 – 58, vol 16
23. Bellesi G., Rigacci L., Alterini R., et al. A new protocol (MICEP) for the treatment of Intermediate or high-grade Non-Hodgkin's lymphoma in the elderly. Leukemia and Lymphoma 1996; 20: 475 – 80
24. Zinzani P. L., Pavone E., Storti S., et al. Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma. Blood 1997; 11: 3974 – 79
25. Kawak L. W., Halpern J., Olshen R. A., et al. Prognostic significance of actual dose intensity in diffuse large cell lymphoma: results of a tree-structured survival analysis. Journal of Clinical Oncology 1990; 8: 963 – 77
26. Tirelli U., Errante D., Van Glabbeke M., et al. CHOP is the standard regimen in patients 70 years of age with intermediate-grade and high-grade Non-Hodgkin's lymphoma: results of randomized study of the European Organization for Research and Treatment of Cancer Lymphomas Cooperative Study Group. Journal of Clinical Oncology 1998; 16: 27 – 34
27. Santini G., Salvagno L., Leoni P., Chisesi T., et al. VACOP-B versus VACOP-B plus Autologous Bone Marrow Trasplantation for Advanced Diffuse Non-Hodgkin's Lymphoma: Results of a Prospective Randomized Trial by the Non-Hodgkin's Lymphoma Cooperative Study Group. Journal of Clinical Oncology 1998; 16: 2796 – 2802
28. Starus D. J., Gaynor J., Leibermann P., et al. Non-Hodgkin's Lymphomas: Characteristics of long-term survivors following conservative treatment. American Journal of Medicine 1987; 82: 247 – 56